ERBB2 and colorectal cancer: Despite the benefits of targeted therapies observed in the majority of solid cancers, including lung, breast and even colorectal cancers, since the 2000s, well-known targeted therapies, such as anti-human epidermal growth factor receptor 2 (HER2) or anti-EGFR agents have only marginally benefited patients with BTC (3).